Addressing large and growing unmet needs

89bio is a clinical-stage biopharmaceutical company focused on rapidly advancing our lead product candidate, BIO89-100, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). BIO89-100 is a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21). We believe it has the potential to have the best clinical profile in the FGF21 class and to be a leader in NASH treatment. BIO89-100 significantly improves liver pathology and addresses the underlying metabolic issues associated with NASH, with a favorable tolerability profile and dosing convenience necessary for adoption and compliance in this chronic, progressive, and generally asymptomatic liver disease. We are also expanding the breadth of indications for BIO89-100 with an initial focus on SHTG.


Rohan Palekar
Ram Waisbourd
Chief Operating Officer and
Chief Business Officer
Dr. Hank Mansbach
Chief Medical Officer
Quoc Le-Nguyen
Chief Technical Operations Officer and
Head of Quality
Ryan Martins
Chief Financial Officer

Board of Directors

Dr. Steven Altschuler (Chairman)
Managing Director, Ziff Capital Partners
Anat Naschitz
Managing Director, OrbiMed
Dr. Greg Grunberg
Managing Director, Longitude Capital
Derek DiRocco, PhD
Principal, RA Capital Management
Dr. Michael Hayden
Lota Zoth
Rohan Palekar